These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23023615)

  • 41. Prostanoid therapy for pulmonary arterial hypertension.
    Strauss WL; Edelman JD
    Clin Chest Med; 2007 Mar; 28(1):127-42; ix. PubMed ID: 17338932
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ACTH deficiency and PGI(2) therapy in chronic thromboembolic pulmonary hypertension.
    Ikari J; Tanabe N; Tatsuno I; Yamanaka M; Sakao S; Tada Y; Kurosu K; Kasahara Y; Takiguchi Y; Tatsumi K
    Int J Cardiol; 2011 Feb; 146(3):449-50. PubMed ID: 21093079
    [No Abstract]   [Full Text] [Related]  

  • 43. [Therapy of severe pulmonary hypertension with prostacyclin and iloprost].
    Matthes J; Mathen F; Herzig S; Wassermann K
    Dtsch Med Wochenschr; 2001 May; 126(21):631-7. PubMed ID: 11413752
    [No Abstract]   [Full Text] [Related]  

  • 44. Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play.
    Lázaro Salvador M; Akerström F; Escribano Subías P; Berenguel Senén A; Martinez Mateo V; Rodriguez Padial L
    Arch Bronconeumol (Engl Ed); 2019 Feb; 55(2):102-103. PubMed ID: 30060983
    [No Abstract]   [Full Text] [Related]  

  • 45. Patient safety challenges in treprostinil therapy.
    Roncesvalles A; Lee FW; Camamo J; Priestley G
    Medsurg Nurs; 2008 Apr; 17(2):101-6. PubMed ID: 18517170
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selexipag: First Global Approval.
    Scott LJ
    Drugs; 2016 Mar; 76(3):413-8. PubMed ID: 26846322
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Selexipag in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension and Eisenmenger Syndrome: First Report.
    El-Kersh K; Suliman S; Smith JS
    Am J Ther; 2018; 25(6):e714-e715. PubMed ID: 29521655
    [No Abstract]   [Full Text] [Related]  

  • 48. Treatments for pulmonary arterial hypertension.
    Liu C; Liu K; Ji Z; Liu G
    Respir Med; 2006 May; 100(5):765-74. PubMed ID: 16549344
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prostacyclin therapy for pulmonary arterial hypertension: new directions.
    Gomberg-Maitland M; Preston IR
    Semin Respir Crit Care Med; 2005 Aug; 26(4):394-401. PubMed ID: 16121316
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pulmonary hypertension update.
    Hesselgrave B
    Case Manager; 2005; 16(6):61-6; quiz 67. PubMed ID: 16326325
    [No Abstract]   [Full Text] [Related]  

  • 51. Long term imatinib treatment in pulmonary arterial hypertension.
    Souza R; Sitbon O; Parent F; Simonneau G; Humbert M
    Thorax; 2006 Aug; 61(8):736. PubMed ID: 16877696
    [No Abstract]   [Full Text] [Related]  

  • 52. Pharmacotherapy for pulmonary arterial hypertension.
    Burki TK
    Lancet Respir Med; 2020 Nov; 8(11):e81. PubMed ID: 32857988
    [No Abstract]   [Full Text] [Related]  

  • 53. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.
    Farber HW; Graven KK; Kokolski G; Korn JH
    J Rheumatol; 1999 May; 26(5):1195-6. PubMed ID: 10332990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cutaneous hypersensitivity and eosinophilia associated with treprostinil.
    Das A; Shabbir A; Sehgal S; Highland KB
    Pulm Pharmacol Ther; 2015 Dec; 35():17-8. PubMed ID: 26407925
    [No Abstract]   [Full Text] [Related]  

  • 55. [Education of patients treated with a continuous epoprostenol infusion for pulmonary hypertension].
    Marlier D
    Soins; 2006 May; (705 Suppl):S7-12. PubMed ID: 16771257
    [No Abstract]   [Full Text] [Related]  

  • 56. Use of an implantable wireless pulmonary pressure monitor during transition of therapy in pulmonary arterial hypertension.
    Airhart S; Verlinden N; Badie N; Raina A; Benza R
    J Heart Lung Transplant; 2019 Feb; 38(2):227-230. PubMed ID: 30691597
    [No Abstract]   [Full Text] [Related]  

  • 57. Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution.
    Yanaka K; Guillien A; Soumagne T; Benet J; Piliero N; Picard F; Pison C; Sitbon O; Bouvaist H; Degano B
    Eur Respir J; 2020 Jun; 55(6):. PubMed ID: 32108046
    [No Abstract]   [Full Text] [Related]  

  • 58. New insights into pulmonary hypertension.
    Furlow B
    Lancet Respir Med; 2013 Sep; 1(7):508. PubMed ID: 24461605
    [No Abstract]   [Full Text] [Related]  

  • 59. [Imatinib for pulmonary arterial hypertension].
    Hoeper MM; Opitz C; Olschewski H; Ulrich S; Speich R; Behr J; Halank M; Wilkens H; Klose H; Lange TJ; Grünig E; Seeger W; Ewert R; Borst MM; Welte T; Rosenkranz S; Ghofrani HA
    Dtsch Med Wochenschr; 2014 Dec; 139 Suppl 4():S151-4. PubMed ID: 25489685
    [No Abstract]   [Full Text] [Related]  

  • 60. Has the 6-min walk distance run its course?
    McLaughlin VV
    Chest; 2012 Dec; 142(6):1363-1365. PubMed ID: 23208324
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.